secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055667
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024
--------------------------------------------------------------------------------

- Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.
- R&D expense $5.2M (down 36% YoY); G&A $3.9M (down 26% YoY) reflecting 2023 restructuring.
- SZN-043 Phase 1a completed; Phase 1b enrollment to begin Q2 2024; proof-of-concept data expected H1 2025.
- Potential $10M milestone from Boehringer Ingelheim if lead Fzd-4 Wnt agonist candidate nominated in 2024.
- Preclinical data at ARVO on Wnt mimetic for corneal dystrophies; publication on pulmonary fibrosis in Respiratory Research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/0000950170-24-055667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/srzn-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer